Category Archives: Recent Events

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) — BriaPro Therapeutics Corp. (“ BriaPro ” or the ...

BriaCell Provides Update to its Board of Directors

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study

Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic ...

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust ...

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 ...

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune ...

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in ...